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Abstract   
Adjuvant cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) have proven highly effective 
in rapidly proliferating breast cancer (RPBC). It has also been seen that sequential administration 
of doxorubicin and CMF is superior to their alternation, especially in indolent tumors. In a phase III 
study, we evaluated whether adjuvant epirubicin (E) followed by CMF is superior to the inverse 
sequence in RPBC. Patients with node-negative or 1–3 node-positive RPBC (Thymidine Labeling 
Index[3% or histological grade 3 or S-phase[10% or Ki67[20%) were randomized to receive E (100 
mg/m2 i.v. d1, q21 days for 4 cycles) followed by CMF (600, 40, 600 mg/m2 i.v. d1 and 8, q28 days 
for 4 cycles) (E ? CMF) or CMF followed by E (CMF ? E) or CMF for 6 cycles. From November 1997 
to December 2004, 1066 patients were enrolled: E ? CMF 440, CMF ? E 438, and CMF 188. At a 
median follow-up of 69 months, 5-year OS was 91% (95% CI 88–94) for E ? CMF and 93% (95% CI 
90–95) for CMF ? E, with adjusted hazard ratio of 0.88 (95% CI 0.58–1.35), and DFS was 80% in 
both arms, with adjusted hazard ratio of 0.99 (95% CI 0.73–1.33, Cox model). Adverse events were 
similar, apart from a higher rate of neutropenia in the CMF ? E arm. No  important differences in 
clinical outcome were observed between the two different sequences, making both a valid  option 
in early breast cancer. Further molecular characterization of the tumors might help to identify 
subgroups  achieving higher benefit from either sequence.     
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Introduction   
The interplay between tumor cell kinetics and type and sequence of anticancer drugs affects the 
efficacy of adjuvant chemotherapy. Tumor proliferation is a prognostic marker in breast cancer [1] 
and affects response to chemotherapy [2]. Antimetabolites act primarily in specific cell cycle 
phases and are especially active in rapidly proliferating tumors, as shown by the high efficacy of 
adjuvant cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in patients with node-
negative, rapidly proliferating breast cancer (RPBC) [3, 4]. Anthracyclines have composite 
mechanisms of action whose contribution to their activity in vivo is still not fully understood [5]: 
the inhibition of topoisomerase-2 relies mainly on tumor cell proliferation, whereas other 
mechanisms are less dependent on proliferation. The superiority of sequential over alternating 
regimens was predicted by the model of Norton and Simon [6] and confirmed in clinical trials of 
adjuvant chemotherapy for breast cancer, demonstrating that the sequential administration of 4 
courses of doxorubicin followed by 8 courses of CMF yields superior relapse-free and overall 
survival (OS) rates compared with alternating administration of the same regimens in patients at 
very high risk of recurrence on the basis of nodal involvement [7]. It is therefore important to 
establish which regimen should be used first. In a retrospective analysis of the aforementioned 
trial, the benefit of sequential doxorubicin—CMF was evident mainly in patients with low-
intermediate proliferating tumors [8]. We hypothesized that RPBC patients could benefit more 
from the inverse sequence, receiving CMF first to kill the subpopulation of highly proliferating cells 
and then the anthracycline to kill the CMF-resistant, probably slowly proliferating subpopulation. 
To test this hypothesis, we compared the two sequences within a randomized trial.    
 
Patients and methods   
Study population  Patients were eligible if they had RPBC, as defined, in order of importance, by 
thymidine labeling index (TLI) [3% or histological grade 3 or S-phase [10% or Ki67/ MIB1 [20%. A 
cutoff of 3% for TLI has consistently provided prognostic information in large series of patients 
with early breast cancer [9, 10]. With regard to S-phase, we previously compared different cell 
kinetic variables in a series of breast cancer specimens, observing that a median S-phase of 10% 
corresponded to a median TLI of about 3% [11]. Works on Ki67 are based on varying, often 
arbitrarily chosen cutoffs, and we adopted the threshold of 20% on the basis of literature data and 
also because it corresponded to the intermediate value between the overall population median 
and the median for grade 3 tumors in our series [11]. Further eligibility criteria were: females B70 
years of age; histological diagnosis of invasive breast carcinoma of any size with 1–3 positive 
axillary nodes or node-negative tumors [1 cm; radical tumor resection; no evidence of metastatic 
disease; white blood cell count C3500/ml or neutrophils C1500/ml, platelets C120,000/ml, 
creatinine B the upper normal limit (UNL), transaminases and bilirubin B 1.5 UNL. Patients gave 
their written informed consent and women of child-bearing potential were required to have a 
negative pregnancy test and to use adequate contraceptive measures. Patients were ineligible if 
they had a previous history of invasive breast cancer or other previous or concomitant 
malignancies or concomitant diseases which could interfere with study participation. The study 
was approved by the institutional review boards of each participating center and has been 
registered as a National Cancer Institute trial (NCT01031030).    
 
Study design and treatments   
This was a prospective, randomized, multicenter, openlabel phase III trial comparing the efficacy 
of three treatment arms in patients with RPBC: E for 4 courses followed by CMF for 4 courses (E ? 
CMF), CMF for 4 courses followed by E for 4 courses (CMF ? E), and CMF alone for 6 courses. The 
arm with CMF alone was closed after the results of the EBCSG meta-analysis were published in 
1998 [12], demonstrating the superiority of anthracyclinebased regimens over CMF alone, and the 
primary objective remained the comparison of E ? CMF with CMF ? E. The CMF regimen consisted 
of cyclophosphamide 600 mg/m2 iv, methotrexate 40 mg/m2 iv and 5-fluorouracil 600 mg/m2 iv 
on days 1 and 8, repeated every 4 weeks. Epirubicin was administered every 3 weeks at 100 
mg/m2 iv. Patients with estrogen receptor (ER)-positive tumors received adjuvant tamoxifen for 5 
years after the end of chemotherapy. A gonadotropin-releasing hormone (GnRH) agonist could be 
added in premenopausal patients not achieving amenorrhea after chemotherapy, at the discretion 
of the participating centers. Patients treated with breast conserving surgery and those submitted 
to mastectomy for pT3–4 tumors received radiotherapy. Histopathological exams were performed 
at each participating center and ER and progesterone receptor (PgR) expression was measured by 
immunohistochemistry in the majority of patients (990 [92.9%] patients for ER, and 985 [92.4%] 
patients for PgR), and by the charcoal dextran assay [13] in the remaining cases. HER2/neu 
positivity was determined by immunohistochemistry using Dako Hercep-test or CB11 antibody or 
by fluorescent in situ hybridization. Tumor proliferation was assessed by TLI in 363 patients (34%), 
by histological grade in 601 patients (56%) and by Ki67/MIB1 in 102 patients (10%). Grading was 
considered a surrogate indicator of the proliferative activity based on the strict correlation 
between the two variables [14]. Baseline workup included medical history, physical examination, 
laboratory exams, chest X-ray, abdominal ultrasound, bone scan, mammography, ECG, and 
cardiological consultation. Clinical and laboratory assessments were repeated before each cycle 
and then at 3-month intervals during years 1 and 2, every 6 months during years 3–5, and yearly 
thereafter up to the tenth year. Annual chest X-ray, liver ultrasound, and bone scans were carried 
out for the first 5 years and at the discretion of the investigator thereafter. Mammography was 
performed yearly. Toxicity was recorded at each clinical examination and scored using World 
Health Organization (WHO) criteria [15]. Dose modifications, based on common criteria, were 
outlined in the protocol. Colony-stimulating factors could be used in the event of grade 4 
neutropenia.   
 
Statistical considerations  
The primary endpoint was OS, defined as the time from randomization to the date of last contact 
or of death from any cause. Secondary objectives were disease-free survival (DFS) and toxicity. DFS 
was defined as the time from randomization to the date of locoregional or distant recurrence, 
second invasive breast carcinoma, second primary cancer, and/or death without evidence of 
breast cancer. Analysis of outcome according to clinical, pathological, and biological variables was 
planned in advance, with an explorative intent. The study was performed in accordance with the 
principles of Good Clinical Practice [16], the ethical standards laid down in the 1964 Declaration of 
Helsinki [17], and local legal and regulatory requirements. Within 6 weeks of surgery, patients 
were randomly assigned to the treatment arms on a 1:1:1 basis by a telephone call to the 
Biostatistics and Clinical Trials Unit of the coordinating center in Forlı` using computer-generated 
randomization lists of permutated blocks of varying sizes stratified for participating center, lymph 
node status (nodenegative vs. node-positive) and ER status (ER-negative vs. ER-positive). The 
sequences were concealed from the physicians. Sample size was determined assuming a 5-year OS 
of 75% for patients treated with 6 cycles of CMF and an expected absolute increase of 8% in 
patients treated with E ? CMF or CMF ? E (5% type I error fixed for a twosided test and power of 
80%), planning an accrual of 1200 patients over 3 years. After stopping the CMF arm, the sample 
size was re-determined assuming a 5-year OS of 78% for patients treated with E ? CMF and an 
expected absolute increase of 7% in patients treated with CMF ? E (5% type I error fixed for a two-
sided test and power of 80%). Continuing a 1:1 randomization, a planned accrual period of 36 
months, and a follow-up period of 60 months, it was estimated that 400 patients per arm were 
necessary. Efficacy analyses were performed according to the intention-to-treat principle. Safety 
analyses concerned all patients who received at least one dose of study medication. DFS and OS 
probability and the 95% confidence interval (95% CI) were computed by the Kaplan–Meier 
product-limit method [18]. The chi-square test or Fisher’s exact test were used to compare the 
incidence and severity of side effects [19]. Estimated hazard ratios (HR) (CMF ? E vs. E ? CMF, CMF 
? E and E ? CMF vs. CMF), their 95% CIs and P values were calculated from the Cox proportional 
hazard regression models [20], adjusted according to center, lymph node status, and ER status. No 
interim analysis was planned. No correction for multiple testing was performed in subgroup 
analyses. The relative dose intensity was calculated as the ratio of the delivered dose intensity, 
i.e., the ratio of the total dose delivered over total time to complete chemotherapy, to the 
planned dose intensity. All P values were based on twosided testing, and statistical analyses were 
carried out with SAS Statistical Software (version 9.1, SAS Institute).  
 
Results Study details  
Between November 1997 and December 2004, 1066 patients were entered onto the trial by 22 
participating centers: 440 were allocated to E ? CMF, 438 to CMF ? E, and 188 to CMF (Fig. 1). 
Median follow up was 69 months.  
 
Patient characteristics  
Patients and tumor characteristics were well balanced in the three treatment arms, as reported in 
Table 1. Median age was 52 years (range 26–70) and 47% of patients were premenopausal. Most 
had pT1–2 ductal carcinoma, 47% with nodal involvement. Seventy-nine percent had poorly 
differentiated tumors and median Ki67/MIB1 was 30%. Sixty-two percent had ER-positive (C10% 
nuclei immunostained or C10 fmol/mg protein), 50% PgR-positive (C10% nuclei immunostained or 
C25 fmol/mg protein) and 34% ER/PgR-negative disease. HER2/neu was assessed in about half of 
the patients and was positive in 44%, reflecting the study selection criteria. Sixty-two percent of 
the patients had breast conservative surgery and thirty-eight percent had mastectomy, with 
axillary dissection in all cases. All patients treated with conservative surgery and 1.4% of those 
who underwent mastectomy received radiotherapy, administered in most cases in concomitance 
with the CMF regimen. All clinical, pathologic, and biologic characteristics were well balanced in 
the three treatment arms. About 83% of patients with ER-positive tumors received adjuvant 
tamoxifen, which was combined with a GnRH agonist in a number of premenopausal patients (43% 
in the E ? CMF arm, 47% in the CMF ? E arm, and 27% in the CMF alone arm).  
 
 
 
Chemotherapy administration and safety  
Seventy-nine percent of patients in the E ? CMF arm, eighty-one percent in the CMF ? E arm, and 
eighty-four percent in the CMF arm completed the planned chemotherapy. Three percent in each 
of the two sequential arms and five percent in the CMF arm stopped treatment in advance due to 
toxicity, mainly mucositis (11 patients), nausea and vomiting (6), fever-infection (5), and liver 
toxicity (4). Rarer causes for stopping therapy were neurotoxicity, cardiotoxicity, allergic reactions 
and myelotoxicity (2 cases each), and actinic dermatitis (1). The remaining patients stopped 
treatment for other reasons, e.g., treatment refusal, death, progression, lost to follow up. Median 
relative dose intensity was 0.86 with E ? CMF, 0.88 with CMF ? E, and 0.88 with CMF.  
 
Toxicity  
Sequential treatments yielded a higher proportion of grade 3–4 side-effects compared with CMF 
alone, in particular neutropenia (P = 0.03) and alopecia (P\0.0001) (Table 2). When the two 
sequential arms were compared, the only difference was a higher incidence in grade 4 
neutropenia in the CMF ? E arm (12.0 vs. 7.5%, P = 0.03) with respect to the E ? CMF arm. Other 
grade 4 toxic events included mucositis, increased AST with chronic C hepatitis, osteoarticular 
pain, febrile leukopenia, allergic reaction, asthenia with infection, and actinic dermatitis. One 
treatment-related death due to myelotoxicity was observed in the arm receiving E ? CMF. There 
were no cases of symptomatic congestive heart failure and the rate of subclinical heart 
impairment was similar among the three arms; one patient in each sequential arm stopped 
treatment following grade 2 cardiotoxicity. The rate of chemotherapy-induced amenorrhea was 
35% in the E ? CMF arm, 36% in the CMF ? E arm, and 27% in the CMF arm. One patient in the CMF 
? E arm was diagnosed with acute myeloid leukemia 27 months after the end of chemotherapy.  
 
Efficacy  
Relevant events are reported in Table 3. Five-year OS was 91% (95% CI 88–94) with E ? CMF and 
93% (95% CI 90–95) with CMF ? E, with a hazard ratio adjusted for center, nodes (negative or 
positive) and ER (negative or positive) status of 0.88 (95% CI 0.58–1.35) (Fig. 2a). Fiveyear DFS was 
80% in both arms (95% CI 76–85% for E ? CMF and 76–84% for CMF ? E), with an adjusted hazard 
ratio of 0.99 (95% CI 0.73–1.33) (Fig. 2b). The analyses conducted on the subgroup of patients for 
whom TLI was available yielded equivalent results, as did those conducted separately in the 
subgroup of grade 1–2 tumors and in those of grade 3 tumors (data not shown). Likewise, 
subgroup analyses according to age (\52 vs. C52 years), menopausal status, histology, tumor size, 
nodal status, and hormone receptor status did not show any differences between the two 
sequential arms (Fig. 3). An exploratory analysis was conducted to compare the group of patients 
receiving 6 cycles of CMF with those receiving a sequence schedule (either E ? CMF or CMF ? E) 
enrolled before the closure of the CMF arm. Five-year OS was 90% (95% CI 87–93) with sequential 
regimens and 90% with CMF (95% CI 86–94), with an adjusted hazard ratio of 0.91 (95% CI 0.59–
1.42). Fiveyear DFS was 77% with sequential regimens (95% CI 73–82%) and 78% with CMF (95% CI 
72–84%), with an adjusted hazard ratio of 0.97 (95% CI 0.70–1.35). Subgroup analyses did not 
show statistically significant differences in outcome between the two treatments (data not 
shown).  
 
Discussion  
Since the publication of the study by Bonadonna and collaborators [21] showing the superiority of 
4 courses of doxorubicin followed by 8 courses of CMF over an alternation of the two regimens, 
sequential schedules have become a common option for the adjuvant therapy of early breast 
cancer. Although today the most widely used sequence involves an anthracycline-based scheme 
followed by a taxane, the problem of the best sequence has yet to be resolved. Our study 
addressed the issue of which is the best sequence in two non cross-resistant regimens in patients 
with RPBC, especially important if the two regimens have different efficacy. Delayed 
administration of the most effective regimen following a less effective treatment is thought to 
jeopardize its efficacy [22]. Conversely, computer simulations based on mathematical models for 
tumor growth and treatment suggest the superiority of the ‘‘worst drug rule’’ involving earlier 
administration of the less effective regimen to rapidly eliminate those cells resistant to the 
stronger regimen [23]. 5-Fluorouracil and methotrexate are S-phase-specific drugs especially 
active against highly proliferating cells, while cyclophosphamide is among the alkylating agents 
with the highest specificity for proliferating cells [24]. Benefit from adjuvant CMF seems, in fact, 
directly correlated with TLI [3]. Anthracyclines are active during S-phase but also during other 
phases, including G1, and induce marked cell arrest in G2/M phase [25], suggesting that they may 
be more active against slowly proliferating tumors when compared with CMF. Response to 
neoadjuvant doxorubicin plus vincristine appears to be independent of pretreatment TLI [26], and 
adjuvant treatment of patients with node-negative RPBC comprising fluorouracil, epirubicin, and 
cyclophosphamide produces a delayed benefit, typical of therapies that are active in 
slowergrowing tumors, and independent of proliferative activity [27]. A diverse distribution of 
tumor cells in the different phases of the cell cycle has been observed after neoadjuvant 
chemotherapy with different drugs: an accumulation of cells in S-phase after CMF and a higher 
accumulation in G2/M phase after anthracyclines [28, 29]. We hypothesized that the sequence E ? 
CMF could be highly active in slowly/intermediately proliferating tumors because of the ability of 
the anthracycline to kill the subpopulation of slowly proliferating cells and to produce a partial 
synchronization of the remaining, highly proliferating cells sensitive to the S-phase-specific drugs 
subsequently administered [8]. We also hypothesized that rapidly proliferating tumors could be 
more effectively treated by administering CMF first to kill the subpopulation of highly proliferating 
cells and then the anthracycline to kill the CMF-resistant, probably slowly proliferating 
subpopulation. We did not find important differences between the two sequential treatments in 
terms of either disease-free or overall survival. It must be emphasized that the only variable tested 
in our study was the different sequences of two regimens as the overall number of cycles 
administered and the dose intensity of the drugs used were the same in the two arms. A previous 
study conducted at the Istituto Nazionale Tumori in Milan did not find any difference between 
CMF given every 3 weeks for 12 courses and 8 courses of the same CMF followed by 4 courses of 
doxorubicin in patients with early breast cancer and one to three involved axillary nodes [30]. 
Although the differing patient populations, drug regimens (CMF every 21 days in the Milan studies 
and CMF days 1 and 8 every 28 days in our study) and number of cycles prevent direct 
comparisons from being made between the two trials, our data suggest that the sequence CMF ? 
anthracycline may be as effective as the more frequently used sequence anthracycline ? CMF in 
patients with RPBC, supporting the efficacy of CMF, at least with the schedule used in this study, in 
these tumors. Further molecular characterization of tumor samples is ongoing to ascertain 
potential differences between the two sequences based on biomolecular profiles. There are 
probably a number of reasons behind the lack of superiority of CMF ? E over E ? CMF in RPBC. 
Although anthracyclines have multiple mechanisms of action, inhibition of topoisomerase-II-a is 
one of the most important. Topoisomerase-II-a expression is associated with cell cycle phases, 
peaking in G2/M and at its lowest in G0/G1 [31], and is prevalent in highly proliferating cells [32]. 
Anthracyclines could therefore be as active as antimetabolites in rapidly proliferating cells, in 
addition to being more active against slowly proliferating ones. On the other hand, 
cyclophosphamide is also partially active against slowly proliferating cells, contributing to making 
the two regimens interchangeable. The heterogeneity of proliferation assessment methods in our 
study may have diluted the differences among treatment arms. Different methodological 
problems affect the evaluation of tumor proliferation [33]. Although TLI is reliable and 
reproducible [10, 34], its complexity has hampered its widespread diffusion. Ki-67/MIB-1, while 
significantly associated with outcome in patients with early breast cancer, has more limited 
reproducibility [35]. In conclusion, our study does not show important differences between 
inverse sequences of two non-crossresistant regimens in early RPBC. Taking into account the 
heterogeneity of breast cancer, the cell cycle specificity of some agents and the cell cycle-related 
expression of some targets, e.g., topoisomerase-II-a, it is possible that further molecular 
characterization of the tumors could identify subgroups that benefit from a specific strategy.  
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